Role of Interferon-Alpha-2b in the Prevention of Superficial Carcinoma of the Bladder Recurrence

Abstract

In order to study the tolerability, toxicity and therapeutic efficacy of interferon-α_2b (Intron-A), 20 patients with superficial transitional cell carcinoma (TCC) of the urinary bladder (T_a, T₁) were given intravesically a low dose (9 million IU) of the drug mixed with 30 ml physiological saline for 8 weeks, starting 1 week after transurethral resection (TUR). Follow-up included urine cytology, ultrasonography of the abdomen and cystourethroscopy. Eleven patients (55%) had no signs of recurrence during a follow-up of 6–32 months (mean duration 24 months). Four patients (20%) had superficial tumor recurrence and 5 patients (25%) showed recurrence with progression to invasive tumors. Tolerability was very good, while toxicity in the form of mild flu-like symptoms was observed in only 3 patients. This pilot study showed that, at a low dose, intravesical interferon therapy can significantly lower the recurrence rate in superficial TCC of the urinary bladder with good tolerance and practically no side effects.